I. E. Smith

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

A. Hilary Calvert, S.J. Harland, David R. Newell et al. · Cancer Chemotherapy and Pharmacology · 1982 · 486 citations

Medicine, Medicinal Chemistry, Pharmacology +5

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial

T.J. Powles, S. Ashley, Alwynne Tidy et al. · JNCI Journal of the National Cancer Institute · 2007 · 429 citations

Medicine, Oncology, Preventive Medicine +14

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

S R Johnston, Gloria Saccani‐Jotti, I. E. Smith et al. · PubMed · 1995 · 304 citations

Medicine, Endocrinology, Oncology +17

PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMA

B.M. Bryant, H.T. Ford, Michael Jarman et al. · The Lancet · 1980 · 134 citations

Medicine, Oncology, Pharmacology +4

Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.

A A Daffada, S R Johnston, I. E. Smith et al. · PubMed · 1995 · 106 citations

Life Sciences, Molecular Biology, Oncology +15